We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+8.27%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$21.8B
AUM Growth
+$3.36B
Cap. Flow
+$2.78B
Cap. Flow %
12.74%
Top 10 Hldgs %
12.04%
Holding
3,109
New
1,280
Increased
559
Reduced
519
Closed
699

Sector Composition

Rank Sector Weight
1 Healthcare 20.03%
2 Consumer Discretionary 13.15%
3 Technology 10.68%
4 Financials 9.81%
5 Communication Services 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATHN.U
426
DELISTED
Athena Technology Acquisition Corp. Units, each consisting of one share of Class A Common Stock and
ATHN.U
$10.4M 0.05%
+1,052,114
New +$10.4M
FUTU icon
427
Futu Holdings
FUTU
$13.9B
$10.4M 0.05%
65,355
+40,010
+158% +$4.95M
IDXX icon
428
Idexx Laboratories
IDXX
$42.9B
$10.4M 0.05%
+21,193
New +$10.6M
PWR icon
429
Quanta Services
PWR
$93.9B
$10.4M 0.05%
+117,783
New +$9.38M
COHU icon
430
Cohu
COHU
$2.39B
$10.3M 0.05%
247,111
+220,897
+843% +$9.73M
GSQD.U
431
DELISTED
G Squared Ascend I Inc. Units, each consisting of one Class A ordinary share and one-fifth of one Warrant to acquire one Class A ordinary share
GSQD.U
$10.3M 0.05%
+1,034,035
New +$10.7M
WFG icon
432
West Fraser Timber
WFG
$5.18B
$10.3M 0.05%
+143,726
New +$9.66M
GDXJ icon
433
PUT
VanEck Junior Gold Miners ETF
GDXJ
$7.06B
$10.3M 0.05%
229,300
-1,046,300
-82% -$51.5M
AMRX icon
434
Amneal Pharmaceuticals
AMRX
$5.72B
$10.3M 0.05%
1,532,897
+1,498,033
+4,297% +$8.3M
RL icon
435
Ralph Lauren
RL
$22.2B
$10.3M 0.05%
83,744
-114,861
-58% -$13.1M
CYXT
436
DELISTED
Cyxtera Technologies, Inc. Class A Common Stock
CYXT
$10.3M 0.05%
1,036,525
+36,559
+4% +$383K
CALY
437
Callaway Golf Company
CALY
$3.26B
$10.3M 0.05%
383,492
+184,759
+93% +$5.23M
KIIIU
438
DELISTED
Kismet Acquisition Three Corp. Unit
KIIIU
$10.2M 0.05%
+1,033,718
New +$10.3M
MSDAU
439
DELISTED
MSD Acquisition Corp. Unit
MSDAU
$10.2M 0.05%
+1,000,000
New +$10M
NTR icon
440
Nutrien
NTR
$32.7B
$10.1M 0.05%
188,031
+172,031
+1,075% +$9.36M
SRNGU
441
DELISTED
Soaring Eagle Acquisition Corp. Unit
SRNGU
$10.1M 0.05%
+1,000,000
New +$10.4M
ENPH icon
442
Enphase Energy
ENPH
$4.84B
$10.1M 0.05%
62,157
+47,538
+325% +$8.53M
CSAN icon
443
Cosan
CSAN
$2.96B
$10.1M 0.05%
+622,574
New +$10.1M
GLOB icon
444
Globant
GLOB
$1.35B
$10M 0.05%
+48,387
New +$10.3M
RTPYU
445
DELISTED
Reinvent Technology Partners Y Unit
RTPYU
$10M 0.05%
+1,000,000
New +$10.1M
APGB.U
446
DELISTED
Apollo Strategic Growth Capital II Units, each consisting of one Class A ordinary share, and one-fifth of one warrant
APGB.U
$10M 0.05%
+1,003,720
New +$10.3M
MDT icon
447
Medtronic
MDT
$107B
$10M 0.05%
84,740
-189,379
-69% -$22.2M
OPCH icon
448
Option Care Health
OPCH
$3.4B
$10M 0.05%
563,612
+77,926
+16% +$1.46M
ROSS.U
449
DELISTED
Ross Acquisition Corp II Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant
ROSS.U
$9.96M 0.05%
+1,000,103
New +$9.96M
LVRAU
450
DELISTED
Levere Holdings Corp. Unit
LVRAU
$9.96M 0.05%
+1,000,000
New +$10M

Similar funds

Marshall Wace's Q1 2021 Portfolio in Review

As of Q1 2021, Marshall Wace held 3,109 positions worth $21.8B, up 18% from $18.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace deployed $2.78B of net new capital in Q1 2021, opening 1,280 new positions and adding to 559 existing holdings. Its largest new stake was Paramount Global Class B: 5,936,494 shares worth $268M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $204M trimmed.

  • Marshall Wace's largest Q1 2021 buy was Paramount Global Class B: 5,936,494 shares worth $268M.
  • Marshall Wace added most to Farfetch Limited Class A Ordinary Shares in Q1 2021, an estimated $182M increase.
  • Marshall Wace's biggest Q1 2021 reduction was Thermo Fisher Scientific, cutting an estimated $204M.
  • Marshall Wace fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q1 2021, selling an estimated $76.2M.
  • Marshall Wace's ten largest holdings make up 12% of its $21.8B portfolio in Q1 2021.
  • Marshall Wace opened 1,280 new positions and closed 699 in Q1 2021.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $21.8B.

Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.